Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST) * The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the sedation of agitated patients in the prehospital environment * The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1 o The RASS is a well validated standardized score to measure a patient's agitation * The secondary outcomes are * Time until RASS returns to 0 or 1 if RASS \<0 * Need for additional sedation * Adverse effects (need for intubation, arrhythmia) * Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying haloperidol * Identification of potential study patients will be per state protocols * Exclusion Criteria for the study * Age \<18 * Pregnant * Allergic to study medication * Transport to hospital other than Mercy Fitzgerald Hospital * Unable to reach medical command prior to giving medication * When a paramedic identifies a possible study candidate, the paramedic will consult medical command to see if the patient is appropriate for the study * If the medical command agrees the patient is appropriate for the study, patients will be randomized to * Odd days: Haloperidol 5mg IM (age \<65) or haloperidol 2.5 mg IM (age ≥65) * Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age \<65) or maximum of 2.5mg (age ≥65) * The RASS will be documented by the prehospital providers every 5 minutes until arrival at the hospital * Once the patient arrives at the ED, the RASS will be documented in PICIS® by the emergency department nurse at the time of triage and at a minimum of hourly until the RASS =0 or 1 for 2 consecutive hours * Questions may be directed to Dr. Isenberg at disenberg@mercyhealth.org or at (267) 205-6453 Richmond Agitation Sedation Scale RASS RASS Description * 4 Combative, violent, danger to staff * 3 Pulls or removes tube(s) or catheters; aggressive * 2 Frequent non-purposeful movement * 1 Anxious, apprehensive, but not aggressive 0 Alert and calm * 1 Awakens to voice (eye opening/contact) \>10 sec * 2 Light sedation, briefly awakens to voice (eye opening/contact) \<10 sec * 3 Moderate sedation, movement or eye opening. No eye contact * 4 Deep sedation, no response to voice, but movement or eye opening to physical stimulation * 5 Unarousable, no response to voice or physical stimulation

About this trial record page

What this page shows

Public field values for ClinicalTrials.gov record NCT01501123, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.

What this page does not do

No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.

Where the data comes from

Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.

Last refresh

Last update posted Jul 23, 2019 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.